Suzetrigine · Journavx
Small molecule
Also known as VX-548
Evidence outlook
Approved: Acute Pain
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also in development:Diabetic Peripheral Neuropathic Pain · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT05558410 NCT05558410 · Acute Pain Patients were randomly assigned to suzetrigine, hydrocodone/acetaminophen or placebo, with patients, care providers, investigators and assessors all blinded. A power calculation set a target of about 1,000 patients, and 1,118 were enrolled. Suzetrigine beat placebo on the primary pain endpoint over 48 hours (least-squares mean 118.4 vs 70.1, p<0.0001). Registry: NCT05558410 | 3 | Time-weighted Sum of the Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) From 0 to 48 Hours (SPID48) SUZ Compared to Placebo (0 to 48 hours After First Dose of Study Drug) 2023-08-25 | Time-weighted Sum of the Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) From 0 to 48 Hours (SPID48) SUZ Compared to Placebo (0 to 48 hours After First Dose of Study Drug): Placebo 70.1 units on a scale (Standard Error 6.1) | Suzetrigine (SUZ) 118.4 units on a scale (Standard Error 4.3) | Reliable signal | link ↗ |
View 1 more trial
NCT05553366 NCT05553366 · Acute Pain Patients were randomly assigned to suzetrigine, hydrocodone/acetaminophen or placebo in a double-blind design. A power calculation set a target of about 1,000 patients, and 1,075 were enrolled. Suzetrigine beat placebo on the primary pain endpoint over 48 hours (least-squares mean 99.9 vs 70.6, p=0.0002). Registry: NCT05553366 | 3 | Time-weighted Sum of the Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) From 0 to 48 Hours (SPID48), SUZ Compared to Placebo (0 to 48 hours After First Dose of Study Drug) 2023-12-15 | Time-weighted Sum of the Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) From 0 to 48 Hours (SPID48), SUZ Compared to Placebo (0 to 48 hours After First Dose of Study Drug): Placebo 70.6 units on a scale (Standard Error 6.3) | Suzetrigine (SUZ) 99.9 units on a scale (Standard Error 4.5) | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (14)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (4)
What this study did
What this study did
What this study did
What this study did
Phase 1 (15)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (25)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (2)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 2 (1)
What this study did
Phase 4 (1)
What this study did
Competitive landscape
Other Voltage-gated sodium channel NaV1.8 drugs
JMKX000623, VX-993. Compare all 3 Voltage-gated sodium channel NaV1.8 drugs
2 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Diabetic Peripheral Neuropathic Pain: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Suzetrigine (Journavx): this drug | Phase 3 | Small molecule | Voltage-gated sodium channel NaV1.8 | Partial signal | NCT05660538: Change From Baseline in the Weekly Average of Daily Pain Intensity on a Numeric Pain Rating Scale (NPRS) (Baseline, At Week 12): Pregabalin -2.09 units on a scale (95% CI -2.65--1.52) vs Suzetrigine (SUZ): Low Dose -2.18 units on a scale (95% CI -2.94--1.41) vs Suzetrigine (SUZ): Mid Dose -2.11 units on a scale (95% CI -2.67--1.55) vs Suzetrigine (SUZ): High Dose -2.26 units on a scale (95% CI -2.82--1.70) | |
| Capsaicin (Qutenza) | Approved | Small molecule | TRPV1 (transient receptor potential vanilloid 1) channel | Reliable signal | NCT01533428: Percent Change in the Average Daily Pain Score From Baseline to Between Weeks 2 and 8 (Baseline to between Weeks 2 to 8): Capsaicin 8% -27.44% (Standard Deviation 26.79) vs Placebo -20.85% (Standard Deviation 28.92) NCT01478607: Norfolk QOL-DN total score change from baseline to end of study: 30 min capsaicin + SOC -27.6% (mean difference vs SOC alone -20.9, 90% CI -31.7 to -10.1); 60 min capsaicin + SOC -32.8% (mean difference vs SOC alone -26.1, 90% CI -36.8 to -15.4); SOC alone -6.7%. | |
| Duloxetine (Cymbalta) | Approved | Small molecule | Serotonin/norepinephrine transporter, Serotonin and norepinephrine transporters (SERT/NET) | Partial signal | NCT01179672: Mean Change From Baseline at 12-Week Endpoint in the Weekly Mean of Pain Severity Score (Baseline, 12 weeks): Duloxetine -2.4 units on a scale (Standard Error 0.14) vs Placebo -1.97 units on a scale (Standard Error 0.14) NCT00408993: Change From Baseline to 12 Week Endpoint in Brief Pain Inventory 24-hour Average Pain Score (Baseline and 12 weeks): Duloxetine -2.69 units on a scale (Standard Error 0.19) vs Placebo -2.31 units on a scale (Standard Error 0.18) missed | |
| Pregabalin | Approved | Small molecule | α2δ subunit of voltage-gated calcium channels | Partial signal | No reviewed efficacy summary in this indication | |
| Tapentadol | Approved | Small molecule | Mu-opioid receptor and norepinephrine transporter (NET) | Reliable signal | NCT01041859: Change From Double-Blind Baseline of the Average Pain Intensity Based on an 11-point Numerical Rating Scale(NRS) Over the Last Week of the Maintenance Period at Week 12 (Double-Blind Baseline and 12 weeks (Primary endpoint is the average pain intensity score during the last week of the maintenance period)): DB Tapentadol ER 0.28 units on a scale (Standard Deviation 2.04) vs DB Placebo 1.3 units on a scale (Standard Deviation 2.43) NCT00455520: Change From Baseline (at Randomization) in Average Pain Intensity on an 11-point Numerical Rating Scale (NRS) Over the Last Week of the Double-blind Maintenance Period at Week 12 (Baseline and 12 weeks): Tapentadol ER -0.1 scores on a scale (Standard Deviation 1.69) vs Placebo 1.3 scores on a scale (Standard Deviation 2.41) | |
| Crisugabalin | Phase 3 | Small molecule | α2δ-1 subunit of voltage-gated calcium channels | Reliable signal | NCT04647773: Week 13 change from baseline in average daily pain score (pooled stages): crisugabalin 40 mg/d -2.24 and 80 mg/d -2.16 vs placebo -1.23 (both P < .001) | |
| Mirogabalin | Phase 3 | Small molecule | α2δ-1 subunit of voltage-gated calcium channels | Partial signal | NCT04094662: Average Daily Pain Score (ADPS) change from baseline to week 14, LS mean difference vs placebo: -0.39 (95% CI: -0.74, -0.04), p = 0.0301 NCT02318706: Change in the Average Daily Pain Score (ADPS) From Baseline to Week 14 Following Administration of DS-5565 in Participants With Diabetic Peripheral Neuropathic Pain (Baseline to Week 14 (post-dose 1 [15 mg QD] and post-dose 2 [20 mg and 30 mg])): DS-5565 15mg QD — Week 1: -0.39 units on a scale (Standard Deviation 0.67); Week 2: -0.6 units on a scale (Standard Deviation 0.9); Week 3: -0.78 units on a scale (Standard Deviation 1.02); Week 4: -0.87 units on a scale (Standard Deviation 1.13); Week 5: -0.97 units on a scale (Standard Deviation 1.2); Week 6: -1.01 units on a scale (Standard Deviation 1.32); Week 7: -1.06 units on a scale (Standard Deviation 1.4); Week 8: -1.07 units on a scale (Standard Deviation 1.49); Week 9: -1.13 units on a scale (Standard Deviation 1.49); Week 10: -1.19 units on a scale (Standard Deviation 1.56); Week 11: -1.23 units on a scale (Standard Deviation 1.57); Week 12: -1.24 units on a scale (Standard Deviation 1.6); Week 13: -1.27 units on a scale (Standard Deviation 1.63); Week 14: -1.34 units on a scale (Standard Deviation 1.74) | DS-5565 20 mg (10 mg BID) — Week 1: -0.4 units on a scale (Standard Deviation 0.85); Week 2: -0.72 units on a scale (Standard Deviation 1.12); Week 3: -0.84 units on a scale (Standard Deviation 1.22); Week 4: -0.94 units on a scale (Standard Deviation 1.38); Week 5: -1.06 units on a scale (Standard Deviation 1.5); Week 6: -1.13 units on a scale (Standard Deviation 1.52); Week 7: -1.13 units on a scale (Standard Deviation 1.59); Week 8: -1.26 units on a scale (Standard Deviation 1.59); Week 9: -1.27 units on a scale (Standard Deviation 1.56); Week 10: -1.33 units on a scale (Standard Deviation 1.65); Week 11: -1.36 units on a scale (Standard Deviation 1.64); Week 12: -1.36 units on a scale (Standard Deviation 1.67); Week 13: -1.43 units on a scale (Standard Deviation 1.72); Week 14: -1.47 units on a scale (Standard Deviation 1.69) | DS-5565 30 mg (15 mg BID) — Week 1: -0.6 units on a scale (Standard Deviation 1.01); Week 2: -1 units on a scale (Standard Deviation 1.27); Week 3: -1.33 units on a scale (Standard Deviation 1.49); Week 4: -1.43 units on a scale (Standard Deviation 1.63); Week 5: -1.48 units on a scale (Standard Deviation 1.68); Week 6: -1.58 units on a scale (Standard Deviation 1.73); Week 7: -1.57 units on a scale (Standard Deviation 1.72); Week 8: -1.53 units on a scale (Standard Deviation 1.79); Week 9: -1.63 units on a scale (Standard Deviation 1.76); Week 10: -1.67 units on a scale (Standard Deviation 1.83); Week 11: -1.69 units on a scale (Standard Deviation 1.8); Week 12: -1.82 units on a scale (Standard Deviation 1.84); Week 13: -1.85 units on a scale (Standard Deviation 1.93); Week 14: -1.88 units on a scale (Standard Deviation 1.88) vs Placebo — Week 1: -0.26 units on a scale (Standard Deviation 0.79); Week 2: -0.46 units on a scale (Standard Deviation 0.96); Week 3: -0.57 units on a scale (Standard Deviation 1.08); Week 4: -0.7 units on a scale (Standard Deviation 1.12); Week 5: -0.84 units on a scale (Standard Deviation 1.17); Week 6: -0.92 units on a scale (Standard Deviation 1.25); Week 7: -1.03 units on a scale (Standard Deviation 1.31); Week 8: -1.09 units on a scale (Standard Deviation 1.39); Week 9: -1.16 units on a scale (Standard Deviation 1.42); Week 10: -1.18 units on a scale (Standard Deviation 1.44); Week 11: -1.25 units on a scale (Standard Deviation 1.46); Week 12: -1.28 units on a scale (Standard Deviation 1.5); Week 13: -1.32 units on a scale (Standard Deviation 1.55); Week 14: -1.37 units on a scale (Standard Deviation 1.6) | |
| HL-1186 | Phase 2 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| JMKX000623 | Phase 2 | Small molecule | Voltage-gated sodium channel NaV1.8 | Partial signal | No reviewed efficacy summary in this indication | |
| LY4065967 | Phase 2 | Small molecule | Angiotensin II type 2 receptor (AT2R) (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Nispomeben (NRD135S.E1) | Phase 2 | Small molecule | — | Partial signal | NCT05480228: Primary (11-point NRS pain, change from baseline to week 12): NRD135S.E1 80 mg/day -1.90 (SD 2.38, n=61) vs placebo -1.94 (SD 2.27, n=61); no statistical analysis posted missed NCT02345291: Placebo-corrected change in weekly mean daily pain intensity (11-point NRS) from run-in to Week 3 (mITT, N=86): -0.42 points for 10 mg (95% CI -1.50, 0.66; p=0.438); -0.82 points for 40 mg (95% CI -1.58, -0.07; p=0.034); -0.66 points for 150 mg (95% CI -1.35, 0.03; p=0.061). missed | |
| Pilavapadin | Phase 2 | Small molecule | AP2-associated kinase 1 (AAK1) | Partial signal | NCT06203002: Change from baseline to Week 8 in ADPS: -1.74 (10 mg), -1.70 (20 mg/10 mg titration), -1.38 (20 mg), vs -1.31 (placebo); overall primary endpoint p=0.11 (not significant, as the statistical plan required all arms to separate from placebo) missed NCT04455633: Change From Baseline to Week 6 in ADPS as Measured by the Numerical Rating Scale (Baseline (Week 2 of the Run-in period) to Week 6): LX9211 100 mg/10 mg -1.39 score on a scale (95% CI -1.77 to -1.01) | LX9211 200 mg/20 mg -1.27 score on a scale (95% CI -1.66 to -0.88) vs Placebo -0.72 score on a scale (95% CI -1.08 to -0.36) | |
| Pirenzepine (topical) | Phase 2 | Small molecule | Muscarinic M1 receptor (antagonist) | Partial signal | Featured results are safety only in this race | |
| VX-993 | Phase 2 | Small molecule | Voltage-gated sodium channel NaV1.8 | not yet graded | No reviewed efficacy summary in this indication | |
| AJH-2947 | Phase 1(overall) | Small molecule | — | Partial signal | No reviewed efficacy summary in this indication | |
| HRS-2129 | Phase 1 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| QR-333 | Discontinued | Botanical | — | not yet graded | No reviewed efficacy summary in this indication | |
| Tanezumab | Discontinued | Monoclonal antibody | Nerve growth factor (NGF) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(30 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Journavx (Suzetrigine) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (2)
December 2026 (2)
2027 (19)
January 2027 (2)
February 2027 (1)
What to watch
March 2027 (2)
What to watch
What to watch
April 2027 (1)
What to watch
May 2027 (1)
What to watch
June 2027 (3)
What to watch
What to watch
What to watch
July 2027 (2)
August 2027 (2)
October 2027 (1)
What to watch
November 2027 (1)
What to watch
December 2027 (3)
What to watch
What to watch
What to watch
2028 (6)
January 2028 (1)
What to watch
February 2028 (1)
What to watch
July 2028 (1)
What to watch
August 2028 (1)
What to watch
September 2028 (1)
What to watch
October 2028 (1)
What to watch
2029 (2)
January 2029 (1)
What to watch
April 2029 (1)
What to watch
2030 (1)
December 2030 (1)
What to watch
Regulatory and conference events
(4)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent